Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone

Environmental and Molecular Mutagenesis

Volumn 47, Issue 9, 2006, Pages 718-724

  Bedir, Abdulkerim ^a   Aliyazicioglu, Yuksel ^a   Kahraman, Hakki ^a   Yurdakul, Zafer ^a   Uysal, Mehmet ^a   Suvaci, Duygu Erol ^a   Okuyucu, Ali ^a   Hökelek, Murat ^a   Alvur, Muhlise ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Comet assoy; Genotoxicity; Rosiglitazone; Single cell gel electrophoresis

Indexed keywords

DNA; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; DRUG MECHANISM; DRUG TREATMENT FAILURE; GENOTOXICITY; MALE; NONHUMAN; PERIPHERAL LYMPHOCYTE; RAT; RAT STRAIN;

ANIMALS; COMET ASSAY; DNA DAMAGE; HYPOGLYCEMIC AGENTS; LIVER; LYMPHOCYTES; MALE; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 33845497225     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20261     Document Type: Article

References (36)

1. Balfour JA, Plosker GL. 1999. Rosiglitazone. Drugs 57:921-930.
2. Bonassi S, Hagmar L, Stromberg U, Montagud AH, Tinnerberg H, Forni A, Heikkila P, Wanders S, Wilhardt P, Hansteen IL, Knudsen LE, Norppa H. 2000. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. European Study Group on Cytogenetic Biomarkers and Health. Cancer Res 15:1619-1625.
3. Collins AR. 1999. Oxidative DNA damage, antioxidants, and cancer. BioEssays 21:238-246.
4. Collins AR. 2004. The comet assay for DNA damage and repair: Principles, applications and limitations. Mol Biotechnol 26:249-261.
5. Day C. 1999. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 16:179-192.
6. Evans RM. 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895.
7. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. 2000. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 283:1695-1702.
8. Forman LM, Simmons DA, Diamond RH. 2000. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 132:118-121.
9. Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, Naito S, Kuribayashi S, Moustafa MA, Uchida T, Sawada H, Kamataki T, Funae Y, Fukumoto M. 2004. Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci 95:520-529.
10. Gillies PS, Dunn CJ. 2000. Pioglitazone. Drugs 60:333-343.
11. Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, Sachinidis A. 2001. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn-Schmiedelbergs Arch Pharmacol 363:215-221.
12. Green MHL, Lowe JE, Delaney CA, Green IC. 1996. Comet assay to detect nitric oxide-dependent DNA damage in mammalian cells. Methods Enzymol 269:243-266.
13. Grossman SL, Lessem J. 1997. Mechanism and clinical effects of thiazolidinediones. Exp Opin Invest Drugs 6:1025-1040.
14. Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A, Speit G, Thybaud V, Tice RR. 2003. Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagenesis 18:45-51.
15. Haskins JR, Rowse P, Rahbari R, de la Iglesia FA. 2001. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 75:425-438.
16. Kahn CR, Chen L, Cohen SE. 2000. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106:1305-1307.
17. Kameda N, Okuya S, Oka Y. 2000. Rosiglitazone (BRL-49653). Nippon Rinsho 58:401-404.
18. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, Baillie TA. 2001. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidine ring scission. Chem Res Toxicol 14:62-70.
19. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. 2000. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to United States Food and Drug Administration. Am J Gastroenterol 95:272-276.
20. Konca K, Lankoff A, Banasik A, Lisowska H, Kuszewski T, Gozdz S, Koza Z, Wojcik A. 2003. A cross-platform public domain PC image-analysis program for the comet assay. Mutat Res/Genet Toxicol Environ Mutagen 534:15-20.
21. Lee RF, Steinert S. 2003. Use of the single cell gel electrophoresis/ Comet assay for detecting DNA damage in aquatic (marine and freshwater) animals. Mutat Res 544:43-66.
22. Levovitz HE, Kreider M, Freed MI. 2002. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821.
23. Moller P. 2006. The alkaline comet assay: Towards validation in biomonitoring of DNA damaging exposures. Basic Clin Pharmacol Toxicol 98:336-345.
24. National Diabetes Data Group. 1987. Non-insulin dependent diabetes. National Diabetes Data Group, US Department of Health and Human Services, National Institutes of Health. Publ No 87-241.
25. Patel J, Anderson RJ, Rappaport EB. 1999. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: Twelve-week randomized placebo control study. Diabetes Obes Metab 1:165-172.
26. Plosker GL, Faulds D. 1999. Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57:409-438.
27. Prescribing information available at: http://www.fda.gov/cder/foi/label/ 1999/21071LBL.PDF.
28. Saltiel AR, Olefsky JM. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669.
29. Sheen AJ. 1997. Drug treatment of non-insulin dependent diabetes mellitus in the 1990s: Achievements and future developments. Drugs 54:355-368.
30. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
31. Spencer CM, Markham A. 1997. Troglitazone. Drugs 54:89-101.
32. Spiegelman BM. 1998. PPAR-γ adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514.
33. Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamato K, Sakurada Y, Ui M, Tokumitsu Y. 1999. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 261:833-837.
34. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
35. Watkins PB, Whitcomb RW. 1998. Hepatic dysfunction associated with troglitazone (Letter). N Engl J Med 338:916, 917.
36. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. 2000. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17:40-47.